An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

Friday News Roundup – International

Friday, May 22 2015ISIS takes control of the ancient Syrian city of Palmyra. Several nations agree to take in Southeast Asian migrants. And the U.S. and Cuba move closer to full restoration of diplomatic ties. A panel of journalists joins guest host Indira Lakshmanan for analysis of the week's top international news stories.

Friday News Roundup – Domestic

Friday, May 22 2015The NSA's bulk data collection faces a Friday deadline. A massive airbag recall could take years to complete. And the State Department makes plans to release the first batch of Hillary Clinton's emails. A panel of journalists joins guest host Indira Lakshmanan for analysis of the week's top national news stories.

Steve Inskeep: “Jacksonland”

Thursday, May 21 2015For years President Andrew Jackson was locked in a battle over Indian lands with a Cherokee chief. NPR’s Steve Inskeep on the history of that rivalry, how it led to the "Trail of Tears" and helped set the stage for the Civil War.